BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBIO BridgeBio Pharma, Inc.

交易中 05-13 13:36:47 EDT

69.96

+4.01

+6.08%

最高70.24	最低65.16	成交量166.70万
今开65.46	昨收65.95	日振幅7.70%
总市值136.99亿	流通市值114.03亿	总股本1.96亿
成交额1.13亿	换手率1.02%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":69.96,"timestamp":1778693806057,"preClose":65.95,"halted":0,"volume":1666988,"delay":0,"changeRate":0.060803639120545726,"floatShares":163000000,"shares":195806242,"eps":-3.744652,"marketStatus":"交易中","change":4.01,"latestTime":"05-13 13:36:47 EDT","open":65.46,"high":70.235,"low":65.16,"amount":112914815.78004001,"amplitude":0.076952,"askPrice":69.96,"askSize":35,"bidPrice":69.92,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-3.744652,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778702400000},"marketStatusCode":2,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":65.95,"preHourTrading":{"tag":"盘前","latestPrice":65.29,"preClose":65.95,"latestTime":"09:29 EDT","volume":1323,"amount":87731.971992,"timestamp":1778678941965,"change":-0.66,"changeRate":-0.010008,"amplitude":0.020167},"postHourTrading":{"tag":"盘后","latestPrice":65.95,"preClose":65.95,"latestTime":"19:48 EDT","volume":126908,"amount":8369557.85,"timestamp":1778629725008,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.775086,"impliedVol":0.1883,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BBIO","defaultTab":"news","newsList":[{"id":"1194973640","title":"BridgeBio Pharma, Inc. 将于2026年夏季启动Encaleret治疗慢性甲状旁腺功能减退症的3期Reclaim-HP研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1194973640","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194973640?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:32","pubTimestamp":1778585567,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 宣布，计划于2026年夏季启动其候选药物Encaleret用于治疗慢性甲状旁腺功能减退症（HP）的3期关键性临床试验，该研究代号为Reclaim-HP。\n这项研究旨在评估Encaleret在慢性甲状旁腺功能减退症患者中的疗效与安全性，标志着该药物研发进程中的一个重要里程碑。公司此举旨在进一步验证该疗法的潜力，并为未来的监管申请奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4505","BBIO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187872314","title":"BridgeBio Pharma 公司新药 Encaleret 有望获优先审评，美国市场预计2027年初上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1187872314","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187872314?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:31","pubTimestamp":1778585475,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 旗下新药 Encaleret 的上市申请或将有资格获得美国食品药品监督管理局的优先审评资格。若进展顺利，该药物在美国市场的商业化推出时间预计将定于2027年初。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","BBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177534862","title":"Acoramidis持续展现对ATTR-CM的疾病修饰效应，降低血清TTR变异率并减少门诊心衰恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1177534862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177534862?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:31","pubTimestamp":1778506290,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma旗下药物Acoramidis在治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）方面，持续显示出其疾病修饰作用。最新数据表明，该药物能有效降低血清转甲状腺素蛋白（TTR）的变异水平，同时显著减少了门诊患者心力衰竭恶化的发生频率。这一进展进一步印证了Acoramidis在改变疾病进程方面的潜力，为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4505","BBIO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151422750","title":"Beyonttra™（Acoramidis）成为巴西首个获批治疗ATTR-CM的近完全TTR稳定剂（≥90%）","url":"https://stock-news.laohu8.com/highlight/detail?id=1151422750","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151422750?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:31","pubTimestamp":1778067076,"startTime":"0","endTime":"0","summary":"巴西国家卫生监督局（Anvisa）已正式批准Beyonttra™（Acoramidis）上市，该药物是全球首款近完全转甲状腺素蛋白（TTR）稳定剂，其稳定效率达到90%及以上，用于治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）。这一批准标志着巴西ATTR-CM患者迎来了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO","BK4585","BK4505","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126838464","title":"Bbp-418在针对Lgmd2i/R9的3期Fortify试验中期分析中展现持续疗效与良好安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1126838464","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126838464?lang=zh_cn&edition=full","pubTime":"2026-03-12 02:02","pubTimestamp":1773252162,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. (BBIO) 旗下药物Bbp-418在其针对肢带型肌营养不良症2i/R9型（Lgmd2i/R9）的3期Fortify临床试验的中期分析中，取得了积极结果。数据显示，该候选疗法不仅表现出持续且一致的有效性，还展现出良好的安全性与耐受性特征。这一关键进展为该药物的后续开发及潜在监管申请提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BBIO","BK4505","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196406724","title":"异动解读 | Leerink Partners上调目标价，BridgeBio Pharma盘前大涨5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196406724","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196406724?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:08","pubTimestamp":1772024883,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.（BBIO）今日盘前股价大幅上涨5.40%，引起了市场的关注。消息面上，根据路透社报道，华尔街券商Leerink Partners在周三发布的研究报告中，将BridgeBio Pharma的目标价从95美元上调至98美元。分析师上调目标价通常被视为对公司未来前景的积极信号，这可能是推动该股在盘前交易时段走强的主要原因。此次目标价调整是当日华尔街分析师对多家美国上市公司进行的一系列评级与目标价调整的一部分，反映了市场参与者对相关公司的最新评估。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136384586","title":"BridgeBio Pharma：Encaleret治疗ADH1三期CALIBRATE试验结果积极，公司计划于2026年上半年提交新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1136384586","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136384586?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:35","pubTimestamp":1771968932,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.宣布，其针对ADH1（常染色体显性低尿钙性高钙血症1型）的在研药物Encaleret，在三期CALIBRATE临床试验中取得了积极结果。基于这一关键性研究的成功数据，公司已明确规划，预计将在2026年上半年向监管机构提交新药上市申请（NDA）。\n此次试验结果的突破性进展，为ADH1这一罕见病患者群体带来了新的治疗希望。公司表示，将全力推进后续的申报准备工作，确保按时完成NDA提交。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","BBIO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189175603","title":"BridgeBio计划于2026年下半年与监管机构会面，商讨Infigratinib新药申请及上市许可申请提交方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1189175603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189175603?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:31","pubTimestamp":1770899474,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 宣布，公司拟于2026年下半年与相关监管机构举行会议，旨在讨论其候选药物Infigratinib的新药申请（NDA）及上市许可申请（MAA）的提交计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","BK4505","BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186975642","title":"BridgeBio：Infigratinib耐受性良好，无停药情况，无与研究药物相关的严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1186975642","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186975642?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:30","pubTimestamp":1770899424,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 公布的数据显示，其研究药物Infigratinib在临床研究中展现出良好的耐受性。研究期间，未出现患者因药物原因停药的情况，也未报告任何与研究药物相关的严重不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBIO","BK4588","BK4585","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192799618","title":"BridgeBio公布口服Infigratinib治疗软骨发育不全儿童全球三期关键研究Propel 3的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1192799618","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192799618?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:30","pubTimestamp":1770899420,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc. 宣布其口服药物Infigratinib针对儿童软骨发育不全症的全球三期关键性研究Propel 3取得积极顶线结果。该研究旨在评估Infigratinib的有效性与安全性，为软骨发育不全这一罕见疾病的治疗带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO","BK4505","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100620662","title":"BridgeBio Pharma发行5.5亿美元2033年到期可转换优先票据 用于提前偿还2027年到期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1100620662","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100620662?lang=zh_cn&edition=full","pubTime":"2026-01-16 14:01","pubTimestamp":1768543309,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.宣布完成5.5亿美元2033年到期可转换优先票据的定价发行。此次发债所得资金将主要用于提前偿还公司2027年到期的可转换优先票据，通过债务期限管理优化公司财务结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BBIO","BK4585","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103280374","title":"BridgeBio持续推进长期债务管理战略 拟发行2033年到期可转换优先票据为2027年到期票据提前融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1103280374","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103280374?lang=zh_cn&edition=full","pubTime":"2026-01-15 05:01","pubTimestamp":1768424504,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.（简称BridgeBio）今日宣布延续其长期债务管理策略，公司计划发行2033年到期的可转换优先票据。此次发债旨在为2027年到期可转换优先票据的偿付进行提前融资。\n通过发行新票据置换即将到期的债务，BridgeBio展现出其对资本结构的主动优化能力。这种前瞻性的融资安排既保障了公司研发管线的持续投入，又为投资者传递了稳健经营的信号。\n可转换票据的灵活特性使企业能在降低融资成本的同时，为持有人提供潜在股权增值机会。此次债务管理举措将进一步强化BridgeBio在生物医药领域的长期竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","BK4139","BBIO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517655651","title":"Bridgebio Pharma, Inc.盘中异动 大幅下跌8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517655651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517655651?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271481,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Bridgebio Pharma, Inc.股票出现异动，股价快速下挫8.49%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。其相关个股中，Plus Therapeutics, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Exicure, Inc.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为910.65%、96.25%、44.75%，振幅较大的相关个股有Mbx Biosciences, Inc.、Tiziana Life Sciences Ltd、Astria Therapeutics, Inc.，振幅分别为8.18%、8.09%、7.54%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223122a2628f81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223122a2628f81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BK4588","BK4585","BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516639846","title":"Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.07%报33.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516639846?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:21","pubTimestamp":1741033285,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时21分，Bridgebio Pharma, Inc.股票出现波动，股价急速下跌5.07%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4602.90%、213.18%、183.34%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042127a25da0cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042127a25da0cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4588","BBIO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105365958","title":"异动解读 | BridgeBio Pharma宣布再融资发债,股价盘中下跌5.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105365958","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105365958?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:34","pubTimestamp":1740494090,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma(股票代码:BBIO)今日盘中大跌5.71%,引发投资者关注。\n\n公司宣布,将非公开发行5亿美元6年期可转换债券,用于偿还借款和回购股票。此举导致二级市场抛售潮,令股价承压。据报道,部分债券收益将用于从持有人手中回购最多5000万美元的普通股。\n\n近期该公司业绩向好,医疗用品营收增长,分析师给予较高的目标股价评级。公司还期望旗下罕见性心脏病药物持续销售强劲,有望带来新的增长点。不过市场担心再融资计划或因募资压力而冲击盈利表现,加上回购股票导致股本摊薄,短期内股价承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | BridgeBio Pharma宣布再融资发债,股价盘中下跌5.71%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090324","title":"Bridgebio Pharma, Inc.盘中异动 早盘大幅跳水8.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090324","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090324?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493894,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Bridgebio Pharma, Inc.股票出现异动，股价大幅下跌8.81%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为749.11%、542.73%、463.20%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Maze Therapeutics, Inc.，振幅分别为62.33%、19.20%、8.87%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223134abdc7dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223134abdc7dd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BBIO","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513569487","title":"Bridgebio Pharma, Inc.2024财年实现净利润-5.36亿美元，同比增加16.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513569487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513569487?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:00","pubTimestamp":1740326459,"startTime":"0","endTime":"0","summary":"2月24日，Bridgebio Pharma, Inc.公布财报，公告显示公司2024财年净利润为-5.36亿美元，同比增加16.64%；其中营业收入为2.22亿美元，同比增加2287.10%，每股基本收益为-2.88美元。从资产负债表来看，Bridgebio Pharma, Inc.总负债23.77亿美元，其中短期债务4.65百万美元，资产负债比为0.39，流动比率为4.69。机构评级：截至2025年2月24日，当前有14家机构对Bridgebio Pharma, Inc.目标价做出预测，其中目标均价为53.43美元，其中最低目标价为37.00美元，最高目标价为95.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000125abd9c7d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000125abd9c7d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513156602","title":"花旗：维持BridgeBio Pharma(BBIO.US)评级，由买入调整至买入评级, 目标价由45.00美元调整至49.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513156602","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513156602?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:01","pubTimestamp":1740160873,"startTime":"0","endTime":"0","summary":"花旗：维持BridgeBio Pharma(BBIO.US)评级，由买入调整至买入评级, 目标价由45.00美元调整至49.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22020148321166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513388292","title":"Scotiabank：维持BridgeBio Pharma(BBIO.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由49.00美元调整至52.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513388292","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513388292?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:51","pubTimestamp":1740153113,"startTime":"0","endTime":"0","summary":"Scotiabank：维持BridgeBio Pharma(BBIO.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由49.00美元调整至52.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21235148320798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152762211","title":"BridgeBio Pharma第四季度每股收益$(1.40)未达预期$(1.14)，销售额$5.88百万超预期$3.48百万","url":"https://stock-news.laohu8.com/highlight/detail?id=1152762211","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152762211?lang=zh_cn&edition=full","pubTime":"2025-02-20 20:39","pubTimestamp":1740055154,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma  报告季度每股亏损$，低于分析师普遍预期的$，差22.81%。公司报告季度销售额$5.88百万，超过分析师普遍预期的$3.48百万，高出69.05%。这是较去年同期销售额$1.75百万增长了237.08%。以上内容来自Benzinga Earnings专栏，原文如下：BridgeBio Pharma  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 22.81 percent. This is a 45.83 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $5.88 million which beat the analyst consensus estimate of $3.48 million by 69.05 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BridgeBio Pharma第四季度每股收益$(1.40)未达预期$(1.14)，销售额$5.88百万超预期$3.48百万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.bridgebio.com","stockEarnings":[{"period":"1week","weight":-0.0411},{"period":"1month","weight":-0.1158},{"period":"3month","weight":-0.1006},{"period":"6month","weight":0.0137},{"period":"1year","weight":0.8484},{"period":"ytd","weight":-0.1378}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日在特拉华州成立。该公司是一家处于商业阶段的生物制药公司，旨在发现、创造、测试和提供具有变革性的药物，以治疗具有明确遗传驱动因素的遗传性疾病和癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.043127},{"month":2,"riseRate":0.428571,"avgChangeRate":0.009556},{"month":3,"riseRate":0.428571,"avgChangeRate":0.078186},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.068249},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.03865},{"month":6,"riseRate":0.833333,"avgChangeRate":0.148281},{"month":7,"riseRate":0.571429,"avgChangeRate":0.133769},{"month":8,"riseRate":0.714286,"avgChangeRate":0.038877},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.051108},{"month":10,"riseRate":0.714286,"avgChangeRate":0.041692},{"month":11,"riseRate":0.714286,"avgChangeRate":0.102784},{"month":12,"riseRate":0.714286,"avgChangeRate":0.047197}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}